U.S. Spending Up for Cancer Drugs Lacking Evidence of Survival Benefit
From 2017 to 2019, Medicare spending on 10 accelerated approval drugs with lack of overall survival benefit increased to $569 million
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.